Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement

2008 ◽  
Vol 98 (4) ◽  
pp. 224-227 ◽  
Author(s):  
Tristan D. Yan ◽  
David L. Morris ◽  
Kusamura Shigeki ◽  
Baratti Dario ◽  
Deraco Marcello
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Consensus Statement ◽  
Expert Consensus ◽  
Peritoneal Surface Malignancy ◽  
Peritoneal Surface

scholarly journals Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2471
Author(s):  
Philipp Horvath ◽  
Can Yurttas ◽  
Stefan Beckert ◽  
Alfred Königsrainer ◽  
Ingmar Königsrainer
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
University Hospital ◽  
Peritoneal Surface Malignancy ◽  
Treatment Protocols ◽  
Primary Tumors ◽  
Peritoneal Surface ◽  
Group 2 ◽  
Group 1

(1) Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) Methods: From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the Tübingen University Hospital were analyzed from a prospectively collected database. (3) Results: Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (range, 1–39) in group 1 and 11 (range, 1–39) in group 2 (p = 0.002). Regarding the completeness of cytoreduction (CC), a score of 0 was achieved in 63% vs. 69% for group 1 and 2, respectively (p = 0.010). Median overall survival rates for patients in group 1 and 2 for colon cancer, ovarian cancer, gastric cancer and appendix cancer were 34 and 25 months; 45 months and not reached; 30 and 16 months; 39 months and not reached, respectively. The occurrence of grade-III and -IV complications slightly differed between groups (14.5% vs. 15.6%). No 30-day mortality occurred. (4) Conclusions: Specialized centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores.

Body surface area‐based vs concentration‐based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial

2019 ◽  
Vol 119 (7) ◽  
pp. 999-1010 ◽  
Author(s):  
Lieselotte Lemoine ◽  
Elsy Thijssen ◽  
Robert Carleer ◽  
Karlien Geboers ◽  
Paul Sugarbaker ◽  
...  
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Peritoneal Surface Malignancy ◽  
Peritoneal Surface

scholarly journals Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective

2016 ◽  
Vol 23 (4) ◽  
pp. 233-238 ◽  
Author(s):  
Priya Mistry ◽  
Faheez Mohamed ◽  
Sanjeev Dayal ◽  
Tom D Cecil ◽  
Brendan J Moran
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Peritoneal Surface Malignancy ◽  
Peritoneal Surface
Sign in / Sign up

Export Citation Format

Share Document